(Q40005109)

16 September 2017

title

Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer (English)

1 reference

16 September 2017

0 references

A K Wu

1

1 reference

16 September 2017

A C Reese

2

1 reference

16 September 2017

M R Cooperberg

3

1 reference

16 September 2017

N Sadetsky

4

1 reference

16 September 2017

K Shinohara

5

1 reference

16 September 2017

publication date

1 November 2011

1 reference

Prostate Cancer and Prostatic Diseases

16 September 2017

published in

1 reference

16 September 2017

volume

15

1 reference

16 September 2017

issue

1

1 reference

16 September 2017

page(s)

100-105

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2011.52

16 September 2017

exact match

0 references

cites work

Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Repeat prostate biopsy--when, where, and how.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

PCA3: a molecular urine assay for predicting prostate biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Decision curve analysis: a novel method for evaluating prediction models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Analysis of repeated biopsy results within 1 year after a noncancer diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Development and external validation of an extended repeat biopsy nomogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Accuracy of Digital Rectal Examination and Transrectal Ultrasonography in Localizing Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2011.52

31 March 2020

Identifiers

DOI

10.1038/PCAN.2011.52

1 reference

Dimensions Publication ID

16 September 2017

1005294832

0 references

1 reference